Cypherpunk Technologies Reports $39.4 Million Profit After Zcash Price Surge Drives $46 Million Unrealised Gain

Cypherpunk Technologies Q2 Results Show Zcash Gains Driving Profit

A sharp rise in the value of Cypherpunk Technologies’ Zcash holdings has transformed the company’s quarterly financial picture, turning a loss a year earlier into a $39.4 million profit.

The result also shows how closely the company’s earnings are now tied to movements in the Zcash market, even as its biotechnology business works towards its next clinical stage.

Zcash Revaluation Drives The Return To Profit

Cypherpunk reported net income of $39.4 million, or $0.18 per diluted share, for the second quarter ended 30 June 2026, compared with a net loss of $16.6 million in the same quarter of 2025.

The main driver was a $46.0 million unrealised gain from the fair value of its Zcash treasury.

ZEC rose from $243.35 to $400.09 during the quarter, allowing the company to record the increase in the value of its holdings without selling the tokens.

Cypherpunk revalues its Zcash holdings at each reporting date, meaning changes in the cryptocurrency’s market price can have a direct effect on reported earnings.

The company valued its Zcash holdings at $129.4 million on 30 June, based on the period-end price of $400.09.

By 11 August, its treasury had grown to 323,394.38 ZEC, acquired at an average purchase price of $341.83 per token.

The holdings represented approximately 1.92% of Zcash’s circulating supply.

Operating Business Remains Loss-Making

Despite the strong bottom-line result, Cypherpunk continued to report a loss at the operating level.

Operating expenses resulted in a $4.7 million operating loss for the quarter, showing that the company’s underlying business did not generate the profit reported after the Zcash revaluation.

Research and development spending fell sharply to $0.2 million from $10.5 million a year earlier.

The reduction followed the completion of clinical trials and earlier reductions in headcount.

General and administrative expenses moved in the opposite direction, rising to $4.5 million from $1.8 million, largely because of higher stock-based compensation and payroll costs.

The difference between the operating result and net income is central to the quarter’s figures: the cryptocurrency gain, rather than operating revenue, was responsible for the company moving into profit.

Cash Position Adds A Separate Layer To The Treasury Strategy

Cypherpunk had $7.6 million in cash and cash equivalents at the end of June.

This was separate from the $129.4 million in digital assets receivable representing its Zcash holdings.

Total assets stood at $143.0 million, while stockholders’ equity was $139.3 million.

The figures leave the company with a balance sheet heavily influenced by the value of its digital asset treasury.

The strategy also creates considerable sensitivity to ZEC price movements.

Earlier in 2026, Cypherpunk reported a $77.6 million unrealised loss as Zcash fell from roughly $508 to about $240, contributing to a $77.2 million net loss in the first quarter.

The second-quarter figures show the same accounting mechanism working in the opposite direction as ZEC recovered.

Leap Therapeutics Moves Closer To A Phase 3 Trial

While Zcash dominates the financial results, Cypherpunk’s biotechnology subsidiary, Leap Therapeutics, is preparing for a potential next stage for its cancer drug programme.

Leap reached alignment with the US Food and Drug Administration on the design of a proposed randomised, controlled Phase 3 trial of sirexatamab, also known as DKN-01, in patients with DKK1-high second-line metastatic colorectal cancer.

The proposed study is expected to enrol about 270 patients.

The company also announced the peer-reviewed publication of results from the Phase 2 DeFianCe study.

The findings support DKK1-high patients as a biomarker-defined group for a potential registrational trial, providing the basis for the proposed Phase 3 development strategy.

How Will Leap Fund Its Next Clinical Stage?

Moving the programme into Phase 3 will require additional resources.

Leap has begun a process to determine how it can secure the funding or strategic support needed to advance sirexatamab.

The options under consideration include financing the programme as an independent entity or pursuing a transaction with a pharmaceutical or biotechnology company.

Potential structures include a partnership, licensing arrangement, collaboration, sale or another business combination.

No timetable has been set, and the company has cautioned that financing or a transaction is not assured.

The process also remains separate from Cypherpunk’s Zcash treasury strategy.

For now, Cypherpunk presents investors with two very different sources of value and risk: a large Zcash position capable of materially changing reported earnings as the token price moves, and a biotechnology asset whose future development depends on securing the resources required for Phase 3.